654 reports of this reaction
2.3% of all INSTALAX POLYETHYLENE GLYCOL 3350 reports
#6 most reported adverse reaction
CONSTIPATION is the #6 most commonly reported adverse reaction for INSTALAX POLYETHYLENE GLYCOL 3350, manufactured by ANI Pharmaceuticals, Inc.. There are 654 FDA adverse event reports linking INSTALAX POLYETHYLENE GLYCOL 3350 to CONSTIPATION. This represents approximately 2.3% of all 28,632 adverse event reports for this drug.
Patients taking INSTALAX POLYETHYLENE GLYCOL 3350 who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for INSTALAX POLYETHYLENE GLYCOL 3350, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for INSTALAX POLYETHYLENE GLYCOL 3350:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 654 FDA reports for INSTALAX POLYETHYLENE GLYCOL 3350. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 2.3% of all adverse event reports for INSTALAX POLYETHYLENE GLYCOL 3350, making it a notable side effect.
If you experience constipation while taking INSTALAX POLYETHYLENE GLYCOL 3350, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.